Omar Ford

Omar Ford is MD+DI's managing editor. You can reach him at [email protected].

Hologic Renews Focus for Breast Health with CE Mark Extension

The Marlborough, MA-based company said the LOCalizer radiofrequency identification (RFID) tag for long-term placement has received a CE mark extension. Hologic is the exclusive distributor of the device, which is manufactured by Health Beacons.

Renovia Receives FDA OK for Next Generation Pelvic Digital Therapeutic

The Ieva device uses movement-based sensors and app technology to provide women real-time feedback as they perform their pelvic floor muscle exercises.

Attune Pushing for New Label Indication

The Chicago-based company said it is vying for a new label indication for ensoETM to reduce thermal injury to the esophagus during cardiac ablation procedures. The ensoETM device has FDA clearance for whole body temperature management using the esophageal space.

LivaNova Stops Caisson TMVR Program

The London-based company acquired Caisson a little more than two years ago for about $72 million. LivaNova is ending the Caisson transcatheter mitral valve replacement program because of continued declines in revenue from its valve business over the last five years.

Hologic Set to Divest ‘Underperforming’ Cynosure

Cynosure was supposed to be Hologic’s beauty, but the medical aesthetics company ended up being a beast after it significantly underperformed. Now two years after acquiring Cynosure for $1.65 billion, Hologic is selling the business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for $205 million.

BioVentrix Has Developed a Unique Way to Improve Heart Functionality

The San Ramon, CA-based company received breakthrough device designation for the Revivent TC Transcatheter Ventricular Enhancement System for the treatment of heart failure. The technology obtained CE mark in 2016.

Medtronic Moves Past EPS Estimates

The Dublin-based company raised guidance from $5.54 to $5.60 to a new range of $5.57 to $5.63.

LimFlow Shows ‘PROMISE’ During VIVA

The Paris-based company announced strong six-month data from PROMISE I, an early feasibility study of the Percutaneous Deep Vein Arterialization (pDVA) System.

Thermo Fisher Rumored to Be Interested in Acquiring Qiagen

Waltham, MA-based Thermo Fisher Scientific could be acquiring Qiagen, according to a report from Bloomberg citing people with knowledge of the matter.

Guardant Eyes Approval for Lunar Through ECLIPSE

The liquid biopsy pioneer is developing the Lunar-2 test, which is being evaluated for early colorectal cancer screening.

Apple Deepens Medical Research Commitment Through New App

The tech giant has announced three health studies its U.S. customers can now enroll in through a new research app.

The Journey of Developing a Novel Point-Of-Care Diagnostic

Kfir Oved co-founder and CTO of MeMed is set to describe the decade-long journey of trying to tackle the global healthcare challenge of antibiotics misuse and the rise of antimicrobial resistance at the BioMed Device San Jose next month.